



Rec'd PCT/PTO

19 JUN 2003

#13

09/674616

Sequence listing REVISED.ST25
SEQUENCE LISTING

<110> Amersham plc
Storey, Anthony E
Mendizabal, Marivi
Champion, Susan
Gibson, Alex
Guilbert, Benedicte
Wilson, Ian A
Knox, Peter

<120> Labelled Glutamine and Lysine Analogues

<130> PZ9816

<140> US 09/674,616

<141> 1999-05-14

<150> PCT/GB99/01550

<151> 1999-05-14

<160> 38

<170> PatentIn version 3.1

<210> 1

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> fragment of human antiplasmin

<400> 1

Asn Gln Glu Gln Val Ser Pro Tyr Thr Leu Leu Lys
1 5 10

<210> 2

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> fragment of human antiplasmin

<220>

<221> MOD_RES

<222> (1)..(1)

<223> ACETYLTATION

<220>

<221> MOD_RES

<222> (13)..(13)

<223> AMIDATION

<400> 2

Asn Gln Glu Gln Val Ser Pro Tyr Thr Leu Leu Lys Gly
1 5 10

Sequence listing REVISED.ST25

<210> 3
 <211> 13
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> derivatised antiplasmin sequence

<220>
 <221> MOD_RES
 <222> (1)..(1)
 <223> ACETYLATION

<220>
 <221> MOD_RES
 <222> (13)..(13)
 <223> BLOCKED

<400> 3

Asn Gln Glu Gln Val Ser Pro Tyr Thr Leu Leu Lys Gly
 1 5 10

<210> 4
 <211> 13
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> derivatised antiplasmin sequence

<220>
 <221> MOD_RES
 <222> (13)..(13)
 <223> BLOCKED

<400> 4

Asn Gln Glu Gln Val Ser Pro Tyr Thr Leu Leu Lys Gly
 1 5 10

<210> 5
 <211> 13
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> derivatised antiplasmin sequence

<220>
 <221> MOD_RES
 <222> (1)..(1)
 <223> BLOCKED

<220>

Sequence listing REVISED.ST25

<221> MOD_RES
<222> (13)..(13)
<223> BLOCKED

<400> 5

Asn Gln Glu Gln Val Ser Pro Tyr Thr Leu Leu Lys Gly
1 5 10

<210> 6
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> derivatised antiplasmin sequence

<220>
<221> MOD_RES
<222> (1)..(1)
<223> ACETYLATION

<220>
<221> MOD_RES
<222> (13)..(13)
<223> BLOCKED

<400> 6

Asn Gln Glu Ala Val Ser Pro Tyr Thr Leu Leu Lys Gly
1 5 10

<210> 7
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> derivatised antiplasmin sequence

<220>
<221> MOD_RES
<222> (1)..(1)
<223> ACETYLATION

<220>
<221> MOD_RES
<222> (13)..(13)
<223> BLOCKED

<400> 7

Asn Ala Glu Ala Val Ser Pro Tyr Thr Leu Leu Lys Gly
1 5 10

Sequence listing REVISED.ST25

<210> 8
 <211> 13
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> derivatised antiplasmin sequence

<220>
 <221> MOD_RES
 <222> (1)..(1)
 <223> ACETYLATION

<220>
 <221> MOD_RES
 <222> (13)..(13)
 <223> BLOCKED

<400> 8

Asn Gln Gln Gln Val Ser Pro Tyr Thr Leu Leu Lys Gly
 1 5 10

<210> 9
 <211> 3
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> derivatised antiplasmin sequence

<220>
 <221> MOD_RES
 <222> (1)..(1)
 <223> ACETYLATION

<220>
 <221> MOD_RES
 <222> (3)..(3)
 <223> BLOCKED

<400> 9

Asn Gln Gly
 1

<210> 10
 <211> 6
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> derivatised antiplasmin sequence

<220>
 <221> MOD_RES
 <222> (1)..(1)

Sequence listing REVISED.ST25

<223> ACETYLATION

<220>

<221> MOD_RES

<222> (6)..(6)

<223> BLOCKED

<400> 10

Asn Gln Glu Gln Val Gly
1 5

<210> 11

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> derivatised antiplasmin sequence

<220>

<221> MOD_RES

<222> (1)..(1)

<223> BLOCKED

<220>

<221> MOD_RES

<222> (9)..(9)

<223> BLOCKED

<400> 11

Asn Gln Glu Gln Val Ser Pro Tyr Gly
1 5

<210> 12

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> derivatised antiplasmin sequence

<220>

<221> MOD_RES

<222> (1)..(1)

<223> ACETYLATION

<220>

<221> MOD_RES

<222> (13)..(13)

<223> BLOCKED

<400> 12

Sequence listing REVISED.ST25

Asn Gln Glu Gln Val Ser Pro Leu Thr Leu Leu Lys Gly
1 5 10

<210> 13
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> derivatised antiplasmin sequence

<220>
<221> MISC_FEATURE
<222> (8)..(8)
<223> MISC_FEATURE "Xaa" = 2-napthylalanine

<220>
<221> MOD_RES
<222> (13)..(13)
<223> BLOCKED

<220>
<221> MOD_RES
<222> (1)..(1)
<223> ACETYLATION

<400> 13

Asn Gln Glu Gln Val Ser Pro Xaa Thr Leu Leu Lys Gly
1 5 10

<210> 14
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> derivatised antiplasmin sequence

<220>
<221> MISC_FEATURE
<222> (8)..(8)
<223> MISC_FEATURE "Xaa" = pBr-Phe

<220>
<221> MOD_RES
<222> (1)..(1)
<223> ACETYLATION

<220>
<221> MOD_RES
<222> (13)..(13)
<223> BLOCKED

<400> 14

Sequence listing REVISED.ST25

Asn Gln Glu Gln Val Ser Pro Xaa Thr Leu Leu Lys Gly
1 5 10

<210> 15
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> derivatised antiplasmin sequence

<220>
<221> MISC_FEATURE
<222> (8)..(8)
<223> MISC_FEATURE "Xaa" = I-Tyr

<220>
<221> MOD_RES
<222> (1)..(1)
<223> ACETYLATION

<220>
<221> MOD_RES
<222> (13)..(13)
<223> BLOCKED

<400> 15

Asn Gln Glu Gln Val Ser Pro Xaa Thr Leu Leu Lys Gly
1 5 10

<210> 16
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> derivatised antiplasmin sequence

<220>
<221> MISC_FEATURE
<222> (8)..(8)
<223> MISC_FEATURE "Xaa" = diiodo-Tyr

<220>
<221> MOD_RES
<222> (13)..(13)
<223> BLOCKED

<220>
<221> MOD_RES
<222> (1)..(1)
<223> ACETYLATION

Sequence listing REVISED.ST25

<400> 16

Asn Gln Glu Gln Val Ser Pro Xaa Thr Leu Leu Lys Gly
1 5 10

<210> 17

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> derivatised antiplasmin sequence

<220>

<221> MOD_RES

<222> (1)..(1)

<223> BLOCKED

<220>

<221> MISC_FEATURE

<222> (8)..(8)

<223> Xaa = iodo-tyrosine

<220>

<221> MOD_RES

<222> (13)..(13)

<223> BLOCKED

<400> 17

Asn Gln Glu Gln Val Ser Pro Xaa Thr Leu Leu Lys Gly
1 5 10

<210> 18

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> derivatised antiplasmin sequence

<220>

<221> MOD_RES

<222> (1)..(1)

<223> BLOCKED

<220>

<221> MISC_FEATURE

<222> (8)..(8)

<223> Xaa = diiodo-Tyr

<220>

<221> MOD_RES

<222> (13)..(13)

<223> BLOCKED

Sequence listing REVISED.ST25

<400> 18

Asn Gln Glu Gln Val Ser Pro Xaa Thr Leu Leu Lys Gly
1 5 10

<210> 19

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> derivatised antiplasmin sequence

<220>

<221> MISC_FEATURE

<222> (12)..(12)

<223> MISC_FEATURE "Xaa" = D-Lys

<220>

<221> MOD_RES

<222> (13)..(13)

<223> BLOCKED

<220>

<221> MOD_RES

<222> (1)..(1)

<223> ACETYLATION

<400> 19

Asn Gln Glu Gln Val Ser Pro Tyr Thr Leu Leu Xaa Gly
1 5 10

<210> 20

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> derivatised antiplasmin sequence

<220>

<221> MISC_FEATURE

<222> (8)..(8)

<223> MISC_FEATURE "Xaa" = D-Tyr

<220>

<221> MOD_RES

<222> (13)..(13)

<223> BLOCKED

<220>

<221> MOD_RES

<222> (1)..(1)

<223> ACETYLATION

Sequence listing REVISED.ST25

<220>
 <221> MISC_FEATURE
 <222> (12)..(12)
 <223> MISC_FEATURE "Xaa" = D-Lys

<400> 20

Asn Gln Glu Gln Val Ser Pro Xaa Thr Leu Leu Xaa Gly
 1 5 10

<210> 21
 <211> 13
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> derivatised antiplasmin sequence

<220>
 <221> MISC_FEATURE
 <222> (6)..(6)
 <223> MISC_FEATURE "Xaa" = D-Ser

<220>
 <221> MOD_RES
 <222> (13)..(13)
 <223> BLOCKED

<220>
 <221> MISC_FEATURE
 <222> (8)..(8)
 <223> MISC_FEATURE "Xaa" = D-Tyr

<220>
 <221> MISC_FEATURE
 <222> (12)..(12)
 <223> MISC_FEATURE "Xaa" = D-Lys

<220>
 <221> MOD_RES
 <222> (1)..(1)
 <223> ACETYLATION

<400> 21

Asn Gln Glu Gln Val Xaa Pro Xaa Thr Leu Leu Xaa Gly
 1 5 10

<210> 22
 <211> 13
 <212> PRT
 <213> Artificial Sequence

Sequence listing REVISED.ST25

<220>
<223> derivatised antiplasmin sequence

<220>
<221> MISC_FEATURE
<222> (5)..(5)
<223> MISC_FEATURE "Xaa" = D-Val

<220>
<221> MOD_RES
<222> (13)..(13)
<223> BLOCKED

<220>
<221> MOD_RES
<222> (1)..(1)
<223> ACETYLATION

<220>
<221> MISC_FEATURE
<222> (6)..(6)
<223> MISC_FEATURE "Xaa" = D-Ser

<220>
<221> MISC_FEATURE
<222> (8)..(8)
<223> MISC_FEATURE "Xaa" = D-Tyr

<220>
<221> MISC_FEATURE
<222> (12)..(12)
<223> MISC_FEATURE "Xaa" = D-Lys

<400> 22

Asn Gln Glu Gln Xaa Xaa Pro Xaa Thr Leu Leu Xaa Gly
1 5 10

<210> 23
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> derivatised antiplasmin sequence

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> MISC_FEATURE "Xaa" = D-Asn

<220>
<221> MOD_RES
<222> (13)..(13)
<223> BLOCKED

Sequence listing REVISED.ST25

<220>
 <221> MISC_FEATURE
 <222> (8)..(8)
 <223> MISC_FEATURE "Xaa" = D-Tyr

<220>
 <221> MISC_FEATURE
 <222> (12)..(12)
 <223> MISC_FEATURE "Xaa" = D-Lys

<220>
 <221> MOD_RES
 <222> (1)..(1)
 <223> ACETYLATION

<400> 23

Xaa Gln Glu Gln Val Ser Pro Xaa Thr Leu Leu Xaa Gly
 1 5 10

<210> 24
 <211> 13
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> derivatised antiplasmin sequence

<220>
 <221> MISC_FEATURE
 <222> (8)..(8)
 <223> MISC_FEATURE "Xaa" = D-Tyr

<220>
 <221> MOD_RES
 <222> (13)..(13)
 <223> bAla

<220>
 <221> MOD_RES
 <222> (1)..(1)
 <223> ACETYLATION

<220>
 <221> MOD_RES
 <222> (13)..(13)
 <223> BLOCKED

<220>
 <221> MISC_FEATURE
 <222> (12)..(12)
 <223> MISC_FEATURE "Xaa" = D-Lys

Sequence listing REVISED.ST25

<400> 24

Asn Gln Glu Gln Val Ser Pro Xaa Thr Leu Leu Xaa Ala
1 5 10

<210> 25

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> derivatised antiplasmin sequence

<220>

<221> MISC_FEATURE

<222> (7)..(7)

<223> MISC_FEATURE "Xaa" = D-Tyr

<220>

<221> MOD_RES

<222> (12)..(12)

<223> BLOCKED

<220>

<221> MISC_FEATURE

<222> (11)..(11)

<223> MISC_FEATURE "Xaa" = D-Lys

<220>

<221> MOD_RES

<222> (1)..(1)

<223> BLOCKED

<400> 25

Gln Glu Gln Val Ser Pro Xaa Thr Leu Leu Xaa Gly
1 5 10

<210> 26

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> derivatised antiplasmin sequence

<220>

<221> MISC_FEATURE

<222> (5)..(12)

<223> MISC_FEATURE = D-amino acids

<220>

<221> MOD_RES

<222> (13)..(13)

<223> BLOCKED

Sequence listing REVISED.ST25

<220>
 <221> MOD_RES
 <222> (1)..(1)
 <223> ACETYLATION

<400> 26

Asn Gln Glu Gln Val Ser Pro Tyr Thr Leu Leu Lys Gly
 1 5 10

<210> 27
 <211> 9
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> derivatised antiplasmin sequence

<220>
 <221> MISC_FEATURE
 <222> (2)..(9)
 <223> MISC_FEATURE = D-amino acids

<220>
 <221> MOD_RES
 <222> (9)..(9)
 <223> AMIDATION

<220>
 <221> MOD_RES
 <222> (1)..(1)
 <223> BLOCKED

<400> 27

Gly Lys Leu Leu Thr Tyr Pro Ser Val
 1 5

<210> 28
 <211> 9
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> derivatised antiplasmin sequence

<220>
 <221> MISC_FEATURE
 <222> (5)..(5)
 <223> MISC_FEATURE "Xaa" = D-Val

<220>
 <221> MOD_RES
 <222> (9)..(9)

Sequence listing REVISED.ST25

<223> BLOCKED

<220>

<221> MISC_FEATURE

<222> (6)..(6)

<223> MISC_FEATURE "xaa" = O-methyl serine

<220>

<221> MOD_RES

<222> (1)..(1)

<223> BLOCKED

<400> 28

Asn Gln Gln Gln Xaa Pro Leu Gly
1 5

<210> 29

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> derivatised antiplasmin sequence

<220>

<221> MOD_RES

<222> (1)..(1)

<223> BLOCKED

<220>

<221> MOD_RES

<222> (13)..(13)

<223> AMIDATION

<400> 29

Asn Gln Glu Gln Val Ser Pro Tyr Thr Leu Leu Lys Gly
1 5 10

<210> 30

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> derivatised antiplasmin sequence

<220>

<221> MOD_RES

<222> (1)..(1)

<223> ACETYLATION

<220>

<221> MOD_RES

Sequence listing REVISED.ST25

<222> (13)..(13)
<223> BLOCKED

<400> 30

Asn Gln Glu Gln Val Ser Pro Tyr Thr Leu Leu Lys Gly
1 5 10

<210> 31
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> derivatised antiplasmin sequence

<220>
<221> MOD_RES
<222> (1)..(1)
<223> BLOCKED

<220>
<221> MOD_RES
<222> (13)..(13)
<223> BLOCKED

<400> 31

Asn Gln Glu Gln Val Ser Pro Tyr Ala Ala Ala Ala Gly
1 5 10

<210> 32
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> derivatised antiplasmin sequence

<220>
<221> MOD_RES
<222> (1)..(1)
<223> BLOCKED

<220>
<221> MOD_RES
<222> (9)..(9)
<223> BLOCKED

<400> 32

Asn Gln Glu Gln Val Ser Pro Tyr Gly
1 5

<210> 33

Sequence listing REVISED.ST25

<211> 13
 <212> PRT
 <213> Artificial sequence

<220>
 <223> derivatised antiplasmin sequence

<220>
 <221> MISC_FEATURE
 <222> (13)..(13)
 <223> Xaa = Gly which is cyclised with the Asn at residue 1

<220>
 <221> MISC_FEATURE
 <222> (1)..(1)
 <223> Xaa = Asn, which is cyclised with the Gly at residue 13

<400> 33

Xaa Gln Glu Gln Val Ser Pro Tyr Thr Leu Leu Lys Xaa
 1 5 10

<210> 34
 <211> 10
 <212> PRT
 <213> Artificial sequence

<220>
 <223> derivatised antiplasmin sequence

<220>
 <221> MOD_RES
 <222> (1)..(1)
 <223> ACETYLATION

<220>
 <221> MOD_RES
 <222> (10)..(10)
 <223> BLOCKED

<400> 34

Leu Gly Pro Gly Gln Ser Lys Val Ile Gly
 1 5 10

<210> 35
 <211> 6
 <212> PRT
 <213> Artificial sequence

<220>
 <223> derivatised antiplasmin sequence

<220>
 <221> MISC_FEATURE
 <222> (1)..(1)
 <223> MISC_FEATURE "Xaa" = pyro-Glu

Sequence listing REVISED.ST25

<220>
 <221> MOD_RES
 <222> (6)..(6)
 <223> BLOCKED

<400> 35

Xaa Ala Gln Ile Val Gly
 1 5

<210> 36
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> derivatised antiplasmin sequence

<220>
 <221> MOD_RES
 <222> (1)..(1)
 <223> ACETYLATION

<220>
 <221> MOD_RES
 <222> (12)..(12)
 <223> BLOCKED

<400> 36

Leu Glu Phe Asp Thr Gln Ser Lys Asn Ile Leu Gly
 1 5 10

<210> 37
 <211> 7
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> derivatised antiplasmin sequence

<220>
 <221> MOD_RES
 <222> (1)..(1)
 <223> ACETYLATION

<220>
 <221> MOD_RES
 <222> (7)..(7)
 <223> BLOCKED

<400> 37

Gly Gln Asp Pro Val Lys Gly

Sequence listing REVISED.ST25

1

5

<210> 38
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> derivatised antiplasmin sequence

<220>
 <221> MOD_RES
 <222> (1)..(1)
 <223> ACETYLATION

<220>
 <221> MOD_RES
 <222> (12)..(12)
 <223> BLOCKED

<400> 38

Tyr Glu Val His His Gln Lys Leu Val Phe Phe Gly
 1 5 10